Core Evidence最新文献_第7页

An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II. 伊卡替特治疗遗传性I型和II型血管性水肿急性发作的潜在作用的循证综述。

Core Evidence Pub Date : 2012-01-01 Epub Date: 2012-09-27 DOI: 10.2147/CE.S24743

Bernard Floccard, Etienne Hautin, Laurence Bouillet, Brigitte Coppere, Bernard Allaouchiche

{"title":"An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.","authors":"Bernard Floccard, Etienne Hautin, Laurence Bouillet, Brigitte Coppere, Bernard Allaouchiche","doi":"10.2147/CE.S24743","DOIUrl":"https://doi.org/10.2147/CE.S24743","url":null,"abstract":"Introduction: Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults.Aims: To update the evidence and provide an overview of the available data on icatibant.Evidence review: Peer reviewed articles published and listed in Medline Search and published updated guidelines for the treatment of acute attacks in hereditary angioedema type I and II in adults were reviewed. The validity and quality of evidence were evaluated.Place in therapy: Clinical evidence for the treatment of acute hereditary angioedema attacks with icatibant is strong. Approximately 10% of the patients require a second dose. No serious adverse reactions have been reported. The only significant side effects consistently registered by 90% of patients are transient local pain, swelling, and erythema at the local injection site.Conclusion: Subcutaneously administered 30 mg icatibant has been shown to be a safe and efficacious treatment in clinical trials. It is the only specific treatment authorized for self-administration by the subcutaneous route offering increased patient independence.","PeriodicalId":10764,"journal":{"name":"Core Evidence","volume":"7 ","pages":"105-14"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/CE.S24743","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30970319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. 卡非佐米在治疗复发和难治性淋巴样肿瘤和多发性骨髓瘤中的新作用。

Core Evidence Pub Date : 2011-01-01 Epub Date: 2011-04-04 DOI: 10.2147/CE.S13838

Salvia Jain, Catherine Diefenbach, Jasmine Zain, Owen A O'Connor

引用次数: 44

Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma. 罗米地辛:用于治疗既往治疗过的皮肤T细胞淋巴瘤的潜在证据。

Core Evidence Pub Date : 2011-01-01 Epub Date: 2010-12-22 DOI: 10.2147/CE.S9084

Brian Poligone, Janet Lin, Catherine Chung

{"title":"Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma.","authors":"Brian Poligone, Janet Lin, Catherine Chung","doi":"10.2147/CE.S9084","DOIUrl":"https://doi.org/10.2147/CE.S9084","url":null,"abstract":"Introduction: Cutaneous T cell lymphoma (CTCL) encompasses a heterogeneous group of neoplasms of skin-homing T cells, which includes mycosis fungoides, the most common form, and Sézary syndrome, the leukemia equivalent of mycosis fungoides. Histone deacetylase inhibitors are currently under investigation for their therapeutic value in a variety of conditions. Through multiple mechanisms, they induce apoptosis or inhibition of tumor cell growth. Some studies have also shown histone deacetylase inhibitors to have synergistic activity with existing therapeutic agents in selected conditions. Romidepsin is a histone deacetylase inhibitor with a promising efficacy and safety profile that may represent a valuable treatment alternative for patients with treatment-resistant mycosis fungoides and Sézary syndrome.Aims: To review emerging evidence regarding the use of romidepsin in the management of treatment-resistant CTCL.Evidence review: There is evidence that romidepsin can induce significant and durable responses in patients with refractory CTCL. In two independent Phase II trials including a total of 167 patients with CTCL, there was an overall response rate of 34% with a partial response of 28% and complete response rate of 6%. The most frequent toxicities reported from the Phase II trials were nausea, vomiting, fatigue, anorexia, and dysgeusia.Clinical potential: Romidepsin may be an effective therapeutic option for patients with CTCL who have had treatment failure with multiple standard treatment modalities.","PeriodicalId":10764,"journal":{"name":"Core Evidence","volume":"6 ","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/CE.S9084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29794239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes. 替格瑞洛:作为口服抗血小板治疗减少急性冠状动脉综合征患者主要心脏不良事件的临床潜力证据

Core Evidence Pub Date : 2011-01-01 Epub Date: 2011-03-17 DOI: 10.2147/CE.S9510

Bernardo Lombo, José G Díez

{"title":"Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes.","authors":"Bernardo Lombo, José G Díez","doi":"10.2147/CE.S9510","DOIUrl":"https://doi.org/10.2147/CE.S9510","url":null,"abstract":"Introduction: Ticagrelor, the first direct-acting, reversibly binding oral P2Y12 receptor antagonist, appears to have a favorable efficacy and safety profile.Aims: To update the evidence and provide an overview of the available data on ticagrelor.Evidence review: Peer reviewed articles published and listed under Medline Search, and published updated guidelines for pharmacotherapies in acute coronary syndromes were reviewed.Place in therapy: Clinical evidence is increasing to support the use of new thienopyridines and the direct-acting P2Y12 receptor in the setting of acute coronary syndromes.Conclusion: The options for drugs to inhibit the platelet P2Y12 receptor for adenosine diphosphate are rapidly expanding. Ticagrelor has shown benefits in clinical trials. Its rapid onset of platelet inhibition and short half-life make it an attractive alternative to thienopyridines, especially when rapid inhibition of platelet aggregation or its quick reversal are required.","PeriodicalId":10764,"journal":{"name":"Core Evidence","volume":"6 ","pages":"31-42"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/CE.S9510","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29794242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. 芬戈莫德治疗复发性多发性硬化症的循证评价。

Core Evidence Pub Date : 2011-01-01 Epub Date: 2011-01-06 DOI: 10.2147/CE.S10101

Emilio Portaccio

{"title":"Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis.","authors":"Emilio Portaccio","doi":"10.2147/CE.S10101","DOIUrl":"https://doi.org/10.2147/CE.S10101","url":null,"abstract":"Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the central nervous system and represents one of the most common causes of chronic neurologic disability in young adults. All the current disease-modifying drugs are administered parenterally, and can be associated with varying degrees of injection site or infusion-related reactions. Together with other side effects, the parenteral route of administration is one of the key factors affecting adherence to therapy in multiple sclerosis. Fingolimod (FTY720) is an immunomodulator that acts on sphingosine 1-phosphate (S1P) receptors and is the first oral drug approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis. Downmodulation of S1P receptor type 1 (S1P(1)) slows the egress of lymphocytes from lymph nodes and recirculation to the central nervous system, reduces astrogliosis, and inhibits angiogenesis during chronic neuroinflammation. Fingolimod also regulates the migration of B cells and dendritic cells, and enhances endothelial barrier function. Results from Phase II and III clinical trials provide robust evidence of the efficacy of fingolimod in relapsing-remitting multiple sclerosis. While some caution should be exercised in terms of safety issues, the introduction of fingolimod represents a great advance in the treatment of relapsing-remitting multiple sclerosis. The pharmacologic data on fingolimod and its efficacy and safety in multiple sclerosis are reviewed in this paper.","PeriodicalId":10764,"journal":{"name":"Core Evidence","volume":"6 ","pages":"13-21"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/CE.S10101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29794240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review. 氨曲南(用于吸入溶液)治疗囊性纤维化患者慢性肺部感染:一项基于证据的综述。

Core Evidence Pub Date : 2011-01-01 Epub Date: 2011-08-11 DOI: 10.2147/CE.S11181

Stephen Kirkby, Kimberly Novak, Karen McCoy

{"title":"Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review.","authors":"Stephen Kirkby, Kimberly Novak, Karen McCoy","doi":"10.2147/CE.S11181","DOIUrl":"https://doi.org/10.2147/CE.S11181","url":null,"abstract":"Cystic fibrosis (CF) is a genetic disease caused by abnormal chloride transport across cellular membranes. In the respiratory tract, this molecular defect causes obstruction of the airways by mucus and chronic endobronchial infection. The majority of patients suffer early death from chronic respiratory disease. Pseudomonas aeruginosa is the predominant chronic airway pathogen in older children and adults with CF and is associated with worse outcomes. However, overall survival in CF has been greatly improved in recent decades due in large part to the aggressive treatment of chronic infections such as P. aeruginosa. While intravenous and oral antibiotics are commonly used in the management of CF respiratory infections, inhaled anti-infective therapies offer the benefit of delivering the drug directly to the site of infection and avoiding potential toxicities associated with systemic absorption. Aztreonam lysine (AZLI) has recently been developed as an inhaled antibiotic for chronic use in CF patients with endobronchial P. aeruginosa infection. This paper reviews background data and the clinical studies which contributed to AZLI's formal FDA approval and growing role in the management of CF pulmonary disease.","PeriodicalId":10764,"journal":{"name":"Core Evidence","volume":"6 ","pages":"59-66"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/CE.S11181","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30227451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 26

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. 利昔那肽:用于治疗2型糖尿病的潜在证据。

Core Evidence Pub Date : 2011-01-01 Epub Date: 2011-09-08 DOI: 10.2147/CE.S15525

Anthony H Barnett

{"title":"Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes.","authors":"Anthony H Barnett","doi":"10.2147/CE.S15525","DOIUrl":"https://doi.org/10.2147/CE.S15525","url":null,"abstract":"Lixisenatide is a once-daily glucagon-like peptide 1 (GLP-1) receptor agonist mimicking several favorable actions of endogenous GLP-1 that result in improved glycemic control with little or no hypoglycemia and weight loss. Phase II trials have shown that lixisenatide 20 μg once daily restores first-phase insulin release in patients with type 2 diabetes and improves the second-phase insulin response. Administered once or twice daily for 4 weeks, it significantly reduced postprandial and fasting blood glucose levels, and glycosylated hemoglobin (HbA(1c)). The efficacy and safety of lixisenatide once daily is being assessed in the GETGOAL Phase III clinical trial program. Results have shown beneficial effects on HbA(1c) compared with placebo in combination with commonly used antidiabetes agents, with no increased risk of hypoglycemia and with beneficial weight reduction. Adverse effects were similar to those observed for available GLP-1 receptor agonists, the most frequent being gastrointestinal. Both GLP-1 receptor agonists and long-acting insulin analogs have demonstrated protective effects on beta cells in preclinical studies. This, along with the pronounced effect of lixisenatide on postprandial plasma glucose, provides a rationale for combining it with long-acting basal insulin analogs, in the hope that the additive effects on glycemic control combined with a potential benefit on islet cells may lead to a new treatment approach to control blood glucose better and prevent long-term complications in patients with type 2 diabetes.","PeriodicalId":10764,"journal":{"name":"Core Evidence","volume":"6 ","pages":"67-79"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/CE.S15525","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30227453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 74

Plerixafor for autologous CD34 cell mobilization. Plerixafor用于自体CD34细胞动员。

Core Evidence Pub Date : 2011-01-01 Epub Date: 2011-02-08 DOI: 10.2147/CE.S7801

Huda Salman, Hillard M Lazarus

引用次数: 4

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. 帕尼珠单抗:用于治疗转移性结直肠癌的证据。

Core Evidence Pub Date : 2010-10-21 DOI: 10.2147/ce.s7035

Rossana Berardi, Azzurra Onofri, Mirco Pistelli, Elena Maccaroni, Mario Scartozzi, Chiara Pierantoni, Stefano Cascinu

{"title":"Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.","authors":"Rossana Berardi, Azzurra Onofri, Mirco Pistelli, Elena Maccaroni, Mario Scartozzi, Chiara Pierantoni, Stefano Cascinu","doi":"10.2147/ce.s7035","DOIUrl":"10.2147/ce.s7035","url":null,"abstract":"Panitumumab is the first fully human monoclonal antibody to Epidermal Growth Factor Receptor (EGFR) to enter clinical trials for the treatment of solid tumors. The anti-tumor activity of panitumumab has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in numerous cancer models, particularly lung, kidney and colorectal (CRC). Preclinical and clinical studies have established a role for panitumumab in metastatic colorectal cancer (mCRC) refractory to multiple chemotherapeutic regimens. Based on these encouraging findings, panitumumab was approved by the US Food and Drug Administration for the treatment of patients with epidermal growth factor receptor-expressing mCRC refractory to fluoropyrimidine-, oxaliplatin-, and/or irinotecan-containing chemotherapeutic regimens. The improvement in progression free survival (PFS) and response rate (RR) produced by panitumumab monotherapy was significantly greater in patients with non mutated (wild-type) K-RAS than in those with mutant K-RAS. Therefore implementing routine K-RAS screening and limiting the use of EGFR inhibitors to patients with wild-type K-RAS appears the better strategy for select only the patients who could benefit from the therapy with panitumumab and also may have the potential for cost savings. The purpose of this review was to evaluate the patient-related, disease-related and economic-related evidence for the use of panitumumab in the treatment of metastatic colorectal cancer in clinical practice.","PeriodicalId":10764,"journal":{"name":"Core Evidence","volume":"5 ","pages":"61-76"},"PeriodicalIF":0.0,"publicationDate":"2010-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/ce.s7035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29439711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. 沙格列汀:其治疗2型糖尿病的证据。

Core Evidence Pub Date : 2010-10-21 DOI: 10.2147/ce.s8006

Kristen Kulasa, Steven Edelman

{"title":"Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.","authors":"Kristen Kulasa, Steven Edelman","doi":"10.2147/ce.s8006","DOIUrl":"https://doi.org/10.2147/ce.s8006","url":null,"abstract":"Introduction: The worldwide prevalence of type 2 diabetes mellitus (T2DM) is high, and the chronically poor metabolic control that can result from T2DM is associated with a high risk for microvascular and macrovascular complications. Because of the progressive pathophysiology of T2DM, oral antidiabetic agents often fail to provide sustained glycemic control, indicating the need for new therapies. Saxagliptin (Onglyza™; Bristol-Myers Squibb Company, Princeton, NJ, USA; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) is an oral dipeptidyl peptidase-4 inhibitor, recently approved for the treatment of T2DM.Evidence review: Saxagliptin significantly improves glycemic control vs placebo, as demonstrated by decreasing glycated hemoglobin, fasting plasma glucose, and postprandial plasma glucose levels when used as monotherapy; in initial combination with metformin; and as add-on therapy with metformin, sulfonylurea (SU), or thiazolidinedione (TZD). Saxagliptin also significantly improves β-cell function, is weight neutral, has a low risk for hypoglycemia, and has been shown to have cardiovascular safety.Place in therapy: The clinical profile for saxagliptin indicates that it is useful as an adjunct to diet and exercise as first-line monotherapy and in combination with metformin; or as add-on treatment for patients who cannot achieve glycemic control with a combination of diet and lifestyle changes and metformin, SU, or TZD.","PeriodicalId":10764,"journal":{"name":"Core Evidence","volume":"5 ","pages":"23-37"},"PeriodicalIF":0.0,"publicationDate":"2010-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/ce.s8006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29439708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 39